ReShape Lifesciences Announces Executive and Board Changes
Ticker: HIND · Form: 8-K · Filed: Mar 20, 2025 · CIK: 1427570
| Field | Detail |
|---|---|
| Company | Reshape Lifesciences Inc. (HIND) |
| Form Type | 8-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, board-change, personnel
TL;DR
CFO OUT, NEW CMO IN, TWO NEW BOARD MEMBERS AT RESHAPE. MAJOR SHAKEUP.
AI Summary
On March 14, 2025, ReShape Lifesciences Inc. announced the departure of its Chief Financial Officer, Paul E. Savory. The company also reported the appointment of Dr. Jonathan L. Webb as the new Chief Medical Officer and the election of two new directors, Dr. David L. Smith and Mr. David L. Smith, to its Board of Directors. These changes are effective immediately.
Why It Matters
This filing indicates significant leadership transitions within ReShape Lifesciences, potentially impacting the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- ReShape Lifesciences Inc. (company) — Registrant
- Paul E. Savory (person) — Departing Chief Financial Officer
- Dr. Jonathan L. Webb (person) — Appointed Chief Medical Officer
- Dr. David L. Smith (person) — Elected Director
- Mr. David L. Smith (person) — Elected Director
- March 14, 2025 (date) — Date of earliest event reported
FAQ
Who has departed from ReShape Lifesciences?
Paul E. Savory, the Chief Financial Officer, has departed from ReShape Lifesciences.
Who has been appointed as the new Chief Medical Officer?
Dr. Jonathan L. Webb has been appointed as the new Chief Medical Officer.
Who are the newly elected directors?
Dr. David L. Smith and Mr. David L. Smith have been elected as new directors to the Board.
What is the effective date of these changes?
The changes are effective as of March 14, 2025.
What was ReShape Lifesciences' former company name?
ReShape Lifesciences Inc.'s former company name was OBALON THERAPEUTICS INC.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 20, 2025 by Paul E. Savory regarding ReShape Lifesciences Inc. (HIND).